| 401 |
Apheresis |
Allogeneic
|
Acute Myelogenous Leukemia
|
Hematology
|
2026
|
Standard Therapy
|
Canada
|
26 |
| 402 |
Apheresis |
Allogeneic
|
Hodgkin Lymphoma
|
Hematology
|
2026
|
Standard Therapy
|
Poland
|
40 |
| 403 |
Apheresis |
Allogeneic
|
Acute Myelogenous Leukemia
|
Hematology
|
2026
|
Standard Therapy
|
Netherlands
|
68 |
| 404 |
Apheresis |
Allogeneic
|
Acute Myelogenous Leukemia
|
Hematology
|
2026
|
Standard Therapy
|
United Kingdom
|
56 |
| 405 |
Apheresis |
Allogeneic
|
Myelodysplastic/Myeloproliferative Neoplasms
|
Hematology
|
2026
|
Standard Therapy
|
Spain
|
65 |
| 406 |
Apheresis |
Allogeneic
|
Acute Myelogenous Leukemia
|
Hematology
|
2026
|
Standard Therapy
|
Germany
|
63 |
| 407 |
Apheresis |
Allogeneic
|
Acute Myelogenous Leukemia
|
Hematology
|
2026
|
Standard Therapy
|
Germany
|
58 |
| 408 |
Apheresis |
Allogeneic
|
Acute Myelogenous Leukemia
|
Hematology
|
2026
|
Standard Therapy
|
Poland
|
44 |
| 409 |
Apheresis |
Allogeneic
|
Acute Myelogenous Leukemia
|
Hematology
|
2026
|
Standard Therapy
|
Czechia
|
61 |
| 410 |
Apheresis |
Allogeneic
|
Acute Myelogenous Leukemia
|
Hematology
|
2026
|
Standard Therapy
|
Australia
|
54 |
| 411 |
Apheresis |
Allogeneic
|
Severe Aplastic Anemia
|
Hematology
|
2026
|
Standard Therapy
|
Poland
|
11 |
| 412 |
Apheresis |
Allogeneic
|
Chronic Myeloid Leukemia
|
Hematology
|
2026
|
Standard Therapy
|
USA
|
64 |
| 413 |
Apheresis |
Autologous
|
Multiple Myeloma
|
Hematology
|
2026
|
Standard Therapy
|
Portugal
|
64 |
| 414 |
Apheresis |
autologous
|
Hodgkin Lymphoma
|
Hematology
|
2026
|
Standard Therapy
|
Germany
|
32 |
| 415 |
Apheresis |
autologous
|
Multiple Myeloma
|
Hematology
|
2026
|
Standard Therapy
|
Germany
|
69 |
| 416 |
Apheresis |
allogeneic
|
Acute Myeloid Leukemia
|
Hematology
|
2026
|
Standard Therapy
|
Germany
|
54 |
| 417 |
Apheresis |
autologous
|
Multiple Myeloma
|
Hematology
|
2026
|
Standard Therapy
|
Germany
|
64 |
| 418 |
Apheresis |
autologous
|
Multiple Myeloma
|
Hematology
|
2026
|
Standard Therapy
|
Germany
|
72 |
| 419 |
Apheresis |
autologous
|
Peripheral T-cell Lymphoma
|
Hematology
|
2026
|
Standard Therapy
|
Germany
|
56 |
| 420 |
Apheresis |
autologous
|
Multiple Myeloma
|
Hematology
|
2026
|
Standard Therapy
|
Germany
|
60 |
| 421 |
Apheresis |
autologous
|
Multiple Myeloma
|
Hematology
|
2026
|
Standard Therapy
|
Germany
|
61 |
| 422 |
Apheresis |
autologous
|
Anaplastic Large-Cell Lymphoma
|
Hematology
|
2026
|
Standard Therapy
|
Germany
|
47 |
| 423 |
Apheresis |
autologous
|
Multiple Myeloma
|
Hematology
|
2026
|
Standard Therapy
|
Germany
|
60 |
| 424 |
Apheresis |
allogeneic
|
Vexas-Syndrome with UBA1-Mutation
|
Hematology
|
2026
|
Standard Therapy
|
Germany
|
67 |
| 425 |
Apheresis |
allogeneic
|
Acute Myelogenous Leukemia
|
Hematology
|
2026
|
Standard Therapy
|
USA
|
27 |
| 426 |
Apheresis |
allogeneic
|
Primary Myelofibrosis PMF
|
Hematology
|
2026
|
Standard Therapy
|
Poland
|
57 |
| 427 |
Apheresis |
allogeneic
|
Acute Myelogenous Leukemia
|
Hematology
|
2026
|
Standard Therapy
|
Poland
|
48 |
| 428 |
Apheresis |
allogeneic
|
Acute Myelogenous Leukemia
|
Hematology
|
2026
|
Standard Therapy
|
Switzerland
|
67 |
| 429 |
Apheresis |
allogeneic
|
Acute Myelogenous Leukemia
|
Hematology
|
2026
|
Standard Therapy
|
Germany
|
42 |
| 430 |
Apheresis |
allogeneic
|
MPS-I: Hurler Syndrome
|
Hematology
|
2026
|
Standard Therapy
|
Russia
|
1 |
| 431 |
Apheresis |
allogeneic
|
Acute Lymphoblastic Leukemia
|
Hematology
|
2026
|
Standard Therapy
|
USA
|
29 |
| 432 |
Apheresis |
allogeneic
|
Acute Lymphoblastic Leukemia
|
Hematology
|
2026
|
Standard Therapy
|
USA
|
47 |
| 433 |
Apheresis |
allogeneic
|
Non-Hodgkin Lymphoma
|
Hematology
|
2026
|
Standard Therapy
|
USA
|
66 |
| 434 |
Apheresis |
allogeneic
|
Acute Myelogenous Leukemia
|
Hematology
|
2026
|
Standard Therapy
|
Poland
|
4 |
| 435 |
Apheresis |
allogeneic
|
Acute Myelogenous Leukemia
|
Hematology
|
2026
|
Standard Therapy
|
USA
|
68 |
| 436 |
Apheresis |
allogeneic
|
Myelodysplastic Syndrome
|
Hematology
|
2026
|
Standard Therapy
|
USA
|
63 |
| 437 |
Apheresis |
allogeneic
|
Myelodysplastic Syndrome
|
Hematology
|
2026
|
Standard Therapy
|
Lithuania
|
40 |
| 438 |
Apheresis |
allogeneic
|
Non-Hodgkin Lymphoma
|
Hematology
|
2026
|
Standard Therapy
|
Germany
|
68 |
| 439 |
Apheresis |
allogeneic
|
Chronic Lymphocytic Leukemia
|
Hematology
|
2026
|
Standard Therapy
|
Netherlands
|
61 |
| 440 |
Apheresis |
allogeneic
|
Acute Lymphoblastic leukemia
|
Hematology
|
2026
|
Standard Therapy
|
Germany
|
21 |
| 441 |
Apheresis |
allogeneic
|
Acute Myelogenous Leukemia
|
Hematology
|
2026
|
Standard Therapy
|
USA
|
72 |
| 442 |
Apheresis |
allogeneic
|
Non-Hodgkin Lymphoma
|
Hematology
|
2026
|
Standard Therapy
|
USA
|
36 |
| 443 |
Apheresis |
allogeneic
|
Acute Myelogenous Leukemia
|
Hematology
|
2026
|
Standard Therapy
|
Germany
|
57 |
| 444 |
Apheresis |
allogeneic
|
Acute Lymphoblastic Leukemia
|
Hematology
|
2026
|
Standard Therapy
|
Belgium
|
63 |
| 445 |
Apheresis |
allogeneic
|
Myelodysplastic Syndrome
|
Hematology
|
2026
|
Standard Therapy
|
United Kingdom
|
54 |
| 446 |
Apheresis |
allogeneic
|
Other Malignancy, Specify
|
Hematology
|
2026
|
Standard Therapy
|
USA
|
54 |
| 447 |
Apheresis |
allogeneic
|
Myelodysplastic Syndrome
|
Hematology
|
2026
|
Standard Therapy
|
USA
|
76 |
| 448 |
Apheresis |
allogeneic
|
Myelodysplastic Disorders
|
Hematology
|
2026
|
Standard Therapy
|
France
|
73 |
| 449 |
Apheresis |
allogeneic
|
Myelodysplastic Syndrome
|
Hematology
|
2026
|
Standard Therapy
|
Germany
|
75 |
| 450 |
Apheresis |
allogeneic
|
Hodgkin Lymphoma
|
Hematology
|
2026
|
Standard Therapy
|
Poland
|
47 |
| 451 |
Apheresis |
allogeneic
|
Myelodysplastic Syndrome
|
Hematology
|
2026
|
Standard Therapy
|
USA
|
68 |
| 452 |
Apheresis |
allogeneic
|
Acute Myelogenous Leukemia
|
Hematology
|
2026
|
Standard Therapy
|
Italy
|
40 |
| 453 |
Apheresis |
allogeneic
|
Acute Myeloid Leukemia
|
Hematology
|
2026
|
Standard Therapy
|
Macedonia
|
59 |
| 454 |
Apheresis |
allogeneic
|
Combined Immunodeficiency
|
Hematology
|
2026
|
Standard Therapy
|
Belgium
|
4 |
| 455 |
Apheresis |
allogeneic
|
Myelodysplastic Syndrome
|
Hematology
|
2026
|
Standard Therapy
|
Australia
|
13 |
| 456 |
Apheresis |
allogeneic
|
Acute Myelogenous Leukemia
|
Hematology
|
2026
|
Standard Therapy
|
Poland
|
33 |
| 457 |
Apheresis |
allogeneic
|
Myelodysplastic Syndrome
|
Hematology
|
2026
|
Standard Therapy
|
Italy
|
38 |
| 458 |
Apheresis |
allogeneic
|
Acute Lymphoblastic Leukemia
|
Hematology
|
2026
|
Standard Therapy
|
Russian Federation
|
28 |
| 459 |
Apheresis |
allogeneic
|
Severe Aplastic Anemia
|
Hematology
|
2026
|
Standard Therapy
|
Germany
|
58 |
| 460 |
Apheresis |
allogeneic
|
Acute Myelogenous Leukemia
|
Hematology
|
2026
|
Standard Therapy
|
Austria
|
54 |
| 461 |
Apheresis |
allogeneic
|
Acute Myelogenous Leukemia
|
Hematology
|
2026
|
Standard Therapy
|
USA
|
74 |
| 462 |
Apheresis |
allogeneic
|
Acute Lymphoblastic Leukemia
|
Hematology
|
2026
|
Standard Therapy
|
United Kingdom
|
20 |
| 463 |
Apheresis |
allogeneic
|
Acute Myelogenous Leukemia
|
Hematology
|
2026
|
Standard Therapy
|
USA
|
57 |
| 464 |
Apheresis |
allogeneic
|
Myelodysplastic Syndrome
|
Hematology
|
2026
|
Standard Therapy
|
Germany
|
69 |
| 465 |
Apheresis |
allogeneic
|
Acute Myelogenous Leukemia
|
Hematology
|
2026
|
Standard Therapy
|
Spain
|
64 |
| 466 |
Apheresis |
allogeneic
|
Myelodysplastic Syndrome
|
Hematology
|
2026
|
Standard Therapy
|
Germany
|
56 |
| 467 |
Apheresis |
autologous
|
Myeloma
|
Hematology
|
2026
|
Standard Therapy
|
Portugal
|
42 |
| 468 |
Apheresis |
Autologous
|
Multiple Myeloma
|
Hematology
|
2026
|
Standard Therapy
|
Germany
|
56 |
| 469 |
Apheresis |
Autologous
|
T-Cell Lymphoma
|
Hematology
|
2026
|
Standard Therapy
|
Germany
|
68 |
| 470 |
Apheresis |
Autologous
|
Multiple Myeloma
|
Hematology
|
2026
|
Standard Therapy
|
Germany
|
71 |
| 471 |
Apheresis |
Autologous
|
Multiple Myeloma
|
Hematology
|
2026
|
Standard Therapy
|
Germany
|
61 |
| 472 |
Apheresis |
Allogeneic
|
T-Cell Acute Lymphoblastic Leukemia
|
Hematology
|
2026
|
Standard Therapy
|
Germany
|
24 |
| 473 |
Apheresis |
Autologous
|
Multiple Myeloma
|
Hematology
|
2026
|
Standard Therapy
|
Germany
|
67 |
| 474 |
Apheresis |
Autologous
|
Multiple Myeloma
|
Hematology
|
2026
|
Standard Therapy
|
Germany
|
62 |
| 475 |
Apheresis |
Autologous
|
Plasma Cell Leukemia
|
Hematology
|
2026
|
Standard Therapy
|
Germany
|
43 |
| 476 |
Apheresis |
Autologous
|
Mantle Cell Lymphoma
|
Hematology
|
2026
|
Standard Therapy
|
Germany
|
60 |
| 477 |
Apheresis |
Autologous
|
Multiple Myeloma
|
Hematology
|
2026
|
Standard Therapy
|
Germany
|
68 |
| 478 |
Apheresis |
Autologous
|
Multiple Myeloma
|
Hematology
|
2026
|
Standard Therapy
|
Germany
|
68 |
| 479 |
Apheresis |
Autologous
|
Multiple Myeloma
|
Hematology
|
2026
|
Standard Therapy
|
Germany
|
70 |
| 480 |
Apheresis |
Allogeneic
|
Primary Myelopathic Polycythemia
|
Hematology
|
2026
|
Standard Therapy
|
Germany
|
67 |
| 481 |
Apheresis |
Autologous
|
Multiple Myeloma
|
Hematology
|
2026
|
Standard Therapy
|
Germany
|
61 |
| 482 |
Apheresis |
Autologous
|
Multiple Myeloma
|
Hematology
|
2026
|
Standard Therapy
|
Germany
|
56 |
| 483 |
Apheresis |
Autologous
|
Multiple Myeloma
|
Hematology
|
2026
|
Standard Therapy
|
Germany
|
69 |
| 484 |
Apheresis |
Autologous
|
Multiple Myeloma
|
Hematology
|
2026
|
Standard Therapy
|
Portugal
|
32 |
| 485 |
Apheresis |
Autologous
|
Lymphoma
|
Hematology
|
2026
|
Standard Therapy
|
Portugal
|
64 |
| 486 |
Apheresis |
Autologous
|
Lymphoma
|
Hematology
|
2026
|
Standard Therapy
|
Portugal
|
64 |
| 487 |
Apheresis |
Allogeneic
|
Acute Myelogenous Leukemia
|
Hematology
|
2026
|
Standard Therapy
|
Poland
|
42 |
| 488 |
Apheresis |
Allogeneic
|
Acute Myelogenous Leukemia
|
Hematology
|
2026
|
Standard Therapy
|
Poland
|
65 |
| 489 |
Apheresis |
Allogeneic
|
Chronic myelomonocytic leukemia
|
Hematology
|
2026
|
Standard Therapy
|
Germany
|
73 |
| 490 |
Apheresis |
Allogeneic
|
Acute Myelogenous Leukemia
|
Hematology
|
2026
|
Standard Therapy
|
Spain
|
63 |
| 491 |
Apheresis |
Allogeneic
|
Thalassemia Major
|
Hematology
|
2026
|
Standard Therapy
|
Italy
|
6 |
| 492 |
Apheresis |
Allogeneic
|
Acute Myelogenous Leukemia
|
Hematology
|
2026
|
Standard Therapy
|
USA
|
63 |
| 493 |
Apheresis |
Allogeneic
|
Hemophagocytic Lymphohistiocytosis
|
Hematology
|
2026
|
Standard Therapy
|
India
|
3 |
| 494 |
Apheresis |
Allogeneic
|
Acute Myelogenous Leukemia
|
Hematology
|
2026
|
Standard Therapy
|
Bulgaria
|
32 |
| 495 |
Apheresis |
Allogeneic
|
Mixed-Phenotype Acute Leukemia
|
Hematology
|
2026
|
Standard Therapy
|
Poland
|
40 |
| 496 |
Apheresis |
Allogeneic
|
Chronic Myelomonocytic Leukemia
|
Hematology
|
2026
|
Standard Therapy
|
USA
|
64 |
| 497 |
Apheresis |
Allogeneic
|
Acute Lymphoblastic Leukemia
|
Hematology
|
2026
|
Standard Therapy
|
Ukraine
|
58 |
| 498 |
Apheresis |
Allogeneic
|
Acute Myelogenous Leukemia
|
Hematology
|
2026
|
Standard Therapy
|
Poland
|
62 |
| 499 |
Apheresis |
Allogeneic
|
Acute Myelogenous Leukemia
|
Hematology
|
2026
|
Standard Therapy
|
France
|
45 |
| 500 |
Apheresis |
Allogeneic
|
T-cell non-Hodgkin Lymphoma (Mycosis Fungoides)
|
Hematology
|
2026
|
Standard Therapy
|
Portugal
|
43 |